# Vivodyne

> Vivodyne is a biotech company that grows more than 20 types of lifelike human organ tissues in the lab, then uses robotic automation to dose, cultivate, and analyze more than 10,000 of them at a time. The vast human datasets it generates feed multimodal AI models that predict how new drugs will behave in people - before they ever reach a clinical trial. The pitch is blunt: roughly 95% of therapies that work in animal models fail in human trials, and Vivodyne wants to fix that gap with real human data instead of mice.

- **Founded:** 2020
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Andrei Georgescu (CEO & Co-Founder), Dan Huh (CSO & Co-Founder)
- **Team size:** ~40 employees
- **Products:** Human Organ Models, Robotic Automation Platform, Predictive AI
- **Notable:** Raised a total of roughly $80M across seed and Series A rounds, Bio-engineered more than 20 human organ tissue types, Built robotic automation that can dose and analyze more than 10,000 tissues at once

## Products & services

- **Human Organ Models** — More than 20 bio-engineered human organ tissue types that mimic native human physiology, blending the principles of organoids and organs-on-chips to capture therapy effects at tissue, cellular, organ, and systemic scale.
- **Robotic Automation Platform** — A fully robotic lab system that can dose, cultivate, and analyze more than 10,000 individual human tissues at a time, producing large-scale, reproducible human datasets.
- **Predictive AI** — Multimodal AI models trained on Vivodyne's human tissue data to predict drug safety, efficacy, toxicity, and patient outcomes - applied to high-throughput screening, ADME-Tox, efficacy testing, and biologics delivery.

## Achievements

- Raised a total of roughly $80M across seed and Series A rounds
- Bio-engineered more than 20 human organ tissue types
- Built robotic automation that can dose and analyze more than 10,000 tissues at once
- Attracted collaborations with a majority of the top 10 pharmaceutical companies
- Recognized by Fast Company and the Lush Prize; featured in WSJ and Forbes
- Opening a 23,000 sq ft fully robotic lab at Genesis Marina, South San Francisco

## Latest updates

- **2025-05** — Raised $40M Series A led by Khosla Ventures to scale AI-powered human tissue testing.
- **2025-05** — Announced a 23,000 sq ft fully robotic lab at Genesis Marina in South San Francisco to expand preclinical human testing capacity.
- **2023-10** — Launched publicly with $38M in seed funding to build lab-grown human organs for drug testing.

## Links

- Website: https://vivodyne.com
- LinkedIn: https://www.linkedin.com/company/vivodyne
- Twitter/X: https://twitter.com/vivodyne

---

Profile page: https://yespress.io/vivodyne
Published by YesPress — https://yespress.io
Last updated: 2026-06-10